Bicycle Therapeutics Ltd (BCYC) has released an update.
Stephen Sands has been appointed to the Board of Directors of a company, deemed independent by Nasdaq rules and regulations. He will serve until the 2025 annual general meeting, with roles on the Audit and Strategic Committees and no disclosed conflicts of interest. Sands will receive a total annual cash compensation of $93,500, options for 24,000 shares, and 12,000 restricted share units, all vesting over three years. His director compensation aligns with the company’s established policy for non-employee directors.
For further insights into BCYC stock, check out TipRanks’ Stock Analysis page.
